

PTO/SB/USA (10.01)

Approved for use through 10/31/2002 OMB 0651-0031

U. S. Patent and Trademark Office U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/935,727
		Filing Date	August 24, 2001
		First Named Inventor	Reiner L. Gentz
		Art Unit	1646
		Examiner Name	E. O'Hara
Sheet	1	of	7
		Attorney Docket Number	PF454P2

U.S. PATENT DOCUMENTS					
Examiner Initials	Cite No.	U.S. Patent Document Kind Code ² Number (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
GA	AA	5,741,667	Goeddel et al.	04-21-98	
EA	AB	5,885,800	Emery et al.	03-23-99	

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No.	Foreign Patent Document Office ¹ Number ⁴	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
EA	AC		WO95/33051	Genentech Inc., et al.	12-07-95	
	AD		WO96/34093	Human Genome Sciences, Inc. et al.	10-31-96	
	AE		WO98/30694	Human Genome Sciences, Inc. et al.	07-16-98	
	AF		EP 0 861 850	SmithKline Beecham Corporation	09-02-98	

OTHER REFERENCES - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume/issue number(s), publisher, city and/or country where published	T ³
EA	AG	Genbank Accession Number AA025673 (08-16-96)	
	AH	KWON et al., <i>The Journal of Biological Chemistry</i> , 272:14272-14276 (1997)	
	AI	GenBank Accession Number W67560 (10-16-96)	
	AJ	GenBank Accession Number M91489 (10-29-92)	
	AK	GIESER et al., <i>Genomics</i> , 13(3):873-876 (7-92)	
	AL	HILLER et al., <i>Genome Research</i> , 6:807-828 (1996)	
	AM	PITTI et al., <i>Nature</i> , 396:699-703 (12-17-98)	
	AN	International Search Report mailed July 11, 2000, in corresponding International Application No. PCT/US00/05686	

Examiner	<i>Eileen B. O'Hara</i>	Date Considered	<i>7/16/03</i>
----------	-------------------------	-----------------	----------------

File Copy

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Guide of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIP Standard ST 3). For Japanese patent documents, the abbreviation of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbol as indicated on the document under WIPO Standard ST 16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.

Burden Hour Statement: This form is estimated to take 30 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.

PTO/SB/DUA (10-01)

Approved for use through 10/31/2002 OMB 0631-0031

U. S. Patent and Trademark Office U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	09/935,727	
			Filing Date	August 24, 2001	
			First Named Inventor	Reiner L. Gentz	
			Art Unit	1646	
Examiner Name	E. O'Hara				
Sheet	2	of	7	Attorney Docket Number	PF454P2

U.S. PATENT DOCUMENTS						
Examiner Initials	Cite No. ¹	U.S. Patent Document Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
EMA ↓	AD	5,632,994		REED ET AL.	05-27-97	
	AP	5,874,546		NAGATA ET AL.	02-23-99	
	AQ	5,652,210		BARR ET AL.	07-29-97	
	AR	5,663,070		BARR ET AL.	09-02-97	
	AS	5,620,889		LYNCH ET AL.	04-15-97	
	AT	5,830,469		LYNCH ET AL.	11-03-98	

FOREIGN PATENT DOCUMENTS							
Examiner Initials	Cite No. ¹	Foreign Patent Document Office ³	Number ⁴	Kind Code ⁵ (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
DMA ↓	AU		WO00/46247		MERCK & CO., INC.	08-10-00	
	AV		WO00/34782		ELI LILLY AND COMPANY	06-15-00	
	AW		WO99/14330		GENENTECH, INC.	03-25-99	
	AX		WO00/53755		GENENTECH, INC.	09-14-00	
	AY		WO00/53223		HUMAN GENOME SCIENCES, INC.	09-14-00	
	AZ		WO00/32221		GENENTECH, INC.	06-08-00	
	BA		WO00/53758		GENENTECH, INC.	09-14-00	
	BB		WO00/37094		ELI LILLY AND COMPANY	06-29-00	
	BC		WO00/58465		ELI LILLY AND COMPANY	10-05-00	
	BD		WO00/58466		ELI LILLY AND COMPANY	10-05-00	
	BE		WO00/01817		SCHERING CORPORATION	01-13-00	
	BF		WO99/07738		REGENERON PHARMACEUTICALS, INC.	02-18-99	
	BG		WO99/04001		ZYMOGENETICS, INC.	01-28-99	
	BH		WO99/26977		BIOGEN, INC.	11-24-98	
	BI		WO99/46376		BASF AKTIENGESELLSCHAFT	09-16-99	
	BJ		WO98/56892		HUMAN GENOME SCIENCES, INC.	12-17-98	
	BK		WO99/33980		CHIRON CORPORATION	07-08-99	
	BL		WO99/11791		UNIVERSITY OF WASHINGTON	03-11-99	
	BM		WO99/31128		INCYTE PHARMACEUTICALS, INC.	06-24-99	
	BN		WO00/60079		CHIRON CORPORATION	10-12-00	
	BO		WO99/50413		ELI LILLY AND COMPANY	10-07-99	

Eileen O'Hara

7/16/03

PTO/SB/USA (10-01)

Approved for use through 10/31/2002 OMB 0651-0031

U.S. Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Application Number	09/935,727	
			Filing Date	August 24, 2001	
			First Named Inventor	Reiner L. Gentz	
			Art Unit	1646	
			Examiner Name	E. O'Hara	
Sheet	3	of	7	Attorney Docket Number	PF454P2

OTHER REFERENCES - NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume/issue number(s), publisher, city and/or country where published	T	
EA ↓ ✓	BP	KIKUNO et al., "Prediction of the Coding Sequences of Unidentified Human Genes, XIV, the Complete Sequences of 100 New cDNA Clones from Brain Which Code for Large Proteins <i>in vitro</i> ," DNA Research 6:197-205 (1999)		
	BQ	BAI et al., "Overexpression of M68/DcR3 in human gastrointestinal tract tumors independent of gene amplification and its location in a four-gene cluster," PNAS 97(3):1230-1235 (02-01-00)		
	BR	YU et al., "A Newly Identified Member of Tumor Necrosis Factor Receptor Superfamily (TR6) Suppresses LIGHT-mediated Apoptosis," The Journal of Biological Chemistry 274(20):13733-13736 (05-14-99)		
	BS	RABINOWICH et al., "Lymphocyte Apoptosis Induced by Fas Ligand-expressing Ovarian Carcinoma Cells," J. Clin. Invest. 101(11):2579-2588 (06-98)		
	BT	WALKER et al., "Tumor expression of Fas ligand (CD95L) and the consequences," Current Opinion in Immunology 10:564-572 (1998)		
	BU	GRATAS, et al., "Up-Regulation of Fas (APO-1/CD95) Ligand and Down-Regulation of Fas Expression in Human Esophageal Cancer," Cancer Research 58:2057-2062 (05-15-98)		
	BV	BUZYN et al., "Membrane-Bound Fas (Apo-1/CD95) Ligand on Leukemic Cells: A Mechanism of Tumor Immune Escape in Leukemia Patients," Blood 94(9):3133-3140 (11-01-99)		
Examiner	Elin P.O'Hara		Date Considered	7/16/03

Examiner Initials if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIP Standard ST 3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbol as indicated on the document under WIP Standard ST.10 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.

Burden Hour Statement: This form is estimated to take 20 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.

PTO/SB/05A (10-01)

Approved for use through 10/31/2002 OMB 051-0031

U. S. Patent and Trademark Office U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	09/935,727	
			Filing Date	August 24, 2001	
			First Named Inventor	Reiner L. Gentz	
			Art Unit	1646	
			Examiner Name	E. O'Hara	
Sheet	4	of	7	Attorney Docket Number	PF454P2

U.S. PATENT DOCUMENTS						
Examiner Initials	Cite No. ¹	U.S. Patent Document Kind Code ² (if known)		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS								
Examiner Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁵
		Office ¹	Number ⁴	Kind Code ³ (if known)				
EIA ↓ ↓ ↓	BW		WO00/73452		Genentech et al.	12-7-2000		
	BX		WO00/75316		Genentech et al.	12-14-2000		
	BY		WO01/18041		Eli Lilly and Company et al.	3-15-2001		
	BZ		WO01/18055		Eli Lilly and Company et al.	3-15-2001		
	CA		WO01/10908		Amgen Inc. et al.	2-15-2001		
	CB		WO01/18202		Eli Lilly and Company et al.	3-15-2001		

OTHER REFERENCES - NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume/issue number(s), publisher, city and/or country where published.		
EIA	CC	DUESTERHOEFT ET AL., Genbank Accession Number AL157435, 2-15-2000		

Examiner	Elia B. O'Hara	Date Considered	7/16/03
----------	----------------	-----------------	---------

Examiner Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

Burden Hour estimates: This form is estimated to take 20 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.

PTO/SW/06A (11-01)

Approved for use through 10/31/2001 OMB 06-14-0001

U.S. Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Application Number	09/935,727	
			Filing Date	August 24, 2001	
			First Named Inventor	Reiner L. Gentz	
			Art Unit	1646	
			Examiner Name	E. O'Hara	
Sheet	5	of	7	Attorney Docket Number	PF454P2

U.S. PATENT DOCUMENTS						
Examiner Initials	Cite No.	U.S. Patent Document Number	Kind Code ¹ (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS								
Examiner Initials	Cite No.	Foreign Patent Document Office ¹	Number ⁴	Kind Code ³ (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	7 ⁶

OTHER REFERENCES - NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published		7 ⁶
EDA	CD	ZHANG et al., (June 2001) Modulation of T-cell Responses to Alloantigens by TR6/DcR3. <i>The Journal of Clinical Investigation</i> 107(11):1459-1468		
EDA	CE	CONNOLLY et al., (2001) In Vivo Inhibition of Fas-Ligand-Mediated Killing by TR6, a Fas Ligand Decoy Receptor. <i>The Journal of Pharmacology and Experimental Therapeutics</i> 298(1):25-33		

Examiner	Eileen B. O'Hara	Date Considered	7/16/03
----------	------------------	-----------------	---------

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with best consideration to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIP Standard ST 3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20221.

PTO/SB/08A (10-01)

Approved for use through 10/31/2002 OMB 0851-0031

U.S. Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/935,727
		Filing Date	August 24, 2001
		First Named Inventor	Reiner L. Gentz
		Art Unit	1646
		Examiner Name	E. O'Hara
Sheet 6 of 7	Attorney Docket Number	PF454P2	

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
EJA	CF	09/912,293-	NOT PUBLISHED	ROSEN et al.	Pages 1-75 (pages 1 & 2 partially redacted), portion of Table 2, and SEQ ID NOS. 29783 and 63238
	CG	6,297,367-B1	10-02-2001	TRIBOULEY	
	CH	5,985,614	11-16-1999	ROSEN et al.	
	CI	4,847,325	07-11-1989	SHADLE et al.	

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No.	Foreign Patent Document Country Code ¹ -Number ² -Kind Code ³ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
EJA	CJ	WO00/52028-A1	09/08/2000	HUMAN GENOME SCIENCES, INC.	
EJA	CK	WO01/22920-A2	04/05/2001	HUMAN GENOME SCIENCES, INC.	pages 1-11, 28, 309-334, 358-408, 545-6, 1769 to 2227 and SEQ ID NOS. 227 and 4504
EJA	CL	WO01/28582-A3	04/26/2001	ELI LILLY AND COMPANY	
EJA	CM	WO01/42463-A1	06/14/2001	ELI LILLY AND COMPANY	
EJA	CN	WO01/42434-A1	06/14/2001	MERCK & CO., INC.	
EJA	CO	WO01/68912-A3	09/20/2001	EPIGENOMICS AG	
EJA	CP	WO02/00677-A1	01/03/2002	HUMAN GENOME SCIENCES, INC.	pages 1-16, 950- 957, 1480-1483, 1604, 1716-1726, 2377, 2401- end of specification, and SEQ ID NOS: 937 and 3112
EJA	CQ	WO02/000928-A3	01/03/2002	EPIGENOMICS AG	Abstract & Int'l Search Report
EJA	CR	WO02/09668-A2	02/07/2002	ELI LILLY AND COMPANY	
EJA	CS	WO02/060317-A2	08/08/2002	CORIXA CORPORATION	
EJA	CT	WO02/060947-A3	08/08/2002	ELI LILLY AND COMPANY	
EJA	CU	WO02/060949-A3	08/08/2002	ELI LILLY AND COMPANY	
EJA	CV	WO02/078524-A2	10/10/2002	ZYCOS, INC.	

*EXAMINER Initials: if reference considered, whether or not citation is in conformance with MPEP 909. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See attached Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3). * For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the application number of the patent document. * Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible. * Applicant is to place a check mark here if English language Translation is attached.

Cileen B. O'Hara

7/16/03

PTO/55/USA (10-01)

Approved for use through 10/31/2002 OMB 0651-0031

U. S. Patent and Trademark Office U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/935,727
		Filing Date	August 24, 2001
		First Named Inventor	Reiner L. Gentz
		Art Unit	1646
		Examiner Name	E. O'Hara
Sheet 7 of 7	Attorney Docket Number	PF454P2	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T*
2/19	CW	YU et al., GenBank Accession No. AF134240, May 11, 1999	
	CX	ASHKENAZI and DIXIT, "Apoptosis control by death and decoy receptors," Curr Opin. Cell Biol. 11 (2), 255-260 (1999).	
	CY	SKOLNICK and FETROW, "From genes to protein structure and function: ..." Trends in Biotechnology 18, 34-39 (January 2000)	
	CZ	KIKUNO et al., PIR Accession No. T45294, January 31, 2000.	
	DA	BAI et al., GenBank Accession No. AF217793, February 12, 2000	
	DB	BAI et al., GenBank Accession No. AF217794, February 12, 2000.	
	DC	BAI et al., GenBank Accession No. AF217796, February 21, 2000	
	DD	YAN et al., "Two-Amino Acid Molecular Switch in an Epithelial Morphogen...." Science 290, 523-527, (October 20, 2000).	
	DE	OHSHIMA et al., "Amplification and expression of a decoy receptor for Fas ligand...." Cancer Letters 160, 89-97, (2000).	
	DF	LOCKSLEY et al., "The TNF and TNF Receptor Superfamilies: Integrating Mammalian Biology," Cell 104, 487-501 (February 23, 2001).	
	DG	WALLIS, GenBank Accession No. AL353715, April 18, 2001	
	DH	MATTHEWS, GenBank Accession No. AL121845, July 6, 2001.	
	DI	PITTI et al., GenBank Accession No. NM_032945, July 6, 2001.	
	DJ	PITTI et al., GenBank Accession No. NM_032957, July 17, 2001.	
	OK	ADAMS et al., "Initial assessment of human gene diversity and expression patterns," Nature 377 (6547 Supp) 3-174, (September 28, 1995).	
	DL	ADAMS et al., GenBank Accession No. AA325843, April 20, 1997	
	DM	HILLIER et al., GenBank Accession No. AA025672, February 1, 1997	
	DN	HILLIER et al., GenBank Accession No. AA155646, November 8, 1997	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 603. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*Applicant's unique citation designation number (optional). *Applicant is to place a check mark here if English language Translation is attached

Examiner Signature	Eileen B. O'Hara	Date Considered	7/16/03
--------------------	------------------	-----------------	---------